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INTRODUCTION
Prescription or over-the-counter medications are a necessity for as many as 80% of pregnant women (Anger and Piquette-Miller, 2008) . Human immunodeficiency virus (HIV) infections are prevalent in 20 million women of child-bearing age, world-wide.
Clinically, antiretroviral (ARV) therapy is crucial for the prevention of mother-to-childtransmission (MTCT) of HIV, but information on the disposition of ARVs in pregnancy or the effect of concomitant infections is still largely lacking. Being the front line barrier against xenobiotics and blood-borne toxins between the mother and the fetus, the integrity of the placenta is of utmost importance. Evidence from the literature demonstrates that the placenta expresses a number of transporters, some of which function in the removal of endogenous compounds and xenobiotics. Specifically, several of the ATP-binding cassette (ABC) drug efflux transporters, including P-glycoprotein (Pgp/ MDR1/ ABCB1), the multidrug resistance-associated proteins (MRPs/ ABCCs), and the breast cancer resistance protein (BCRP/ ABCG2) are highly expressed in placental tissues and have been found to profoundly limit the in vivo passage of potentially toxic xenobiotics into the fetus (Petropoulos et al., 2007; Zhou et al., 2008) .
While the role of ABC proteins in drug transport has been examined under normal physiological conditions, the impact of maternal disease on drug transporter regulation and activity is still poorly understood. Infection and inflammation occur frequently in pregnancy and induction of pro-inflammatory cytokines is seen with many prevalent obstetric complications including preeclampsia, gestational diabetes and various infections (Romero et al., 2007) . Previous studies from our group and others have reported inflammation-mediated alterations in the expression and activity of rodent ABC This article has not been copyedited and formatted. The final version may differ from this version. 
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5 drug transporters in the biologically protective barriers of the liver, intestine and brain, as well as the placenta (reviewed in (Petrovic et al., 2007) ). Moreover, altered drug disposition due to the inflammation-mediated suppression of P-glycoprotein was previously observed in vivo, in male mice (Hartmann et al., 2005) .
Currently, the protease inhibitor lopinavir (LPV) is widely used in clinical regimens for pregnant HIV-positive women. LPV is a Biopharmaceutics Classification System class II antiretroviral drug with a therapeutic dose range of approximately 5-7 μg/ml (mean steady state trough concentration) and peak plasma concentration in the range of 10 μg/ml. Maintenance of optimal LPV concentration is essential for effective therapy and MTCT prevention, but little is known about the effects of inflammatory mediators on the pharmacokinetics of this protease inhibitor. Previous in vitro studies have established LPV is a substrate for P-gp and MRP2 (Agarwal et al., 2007; Janneh et al., 2007) . As HIV-positive pregnant women are susceptible to opportunistic infections (Watts et al., 2004) , it is plausible that changes in drug transporters may occur and in turn mediate changes in LPV disposition. Indeed, we have previously shown that the inflammationmediated downregulation of placental Bcrp led to the increased accumulation of the Bcrp substrate, glyburide in rat fetus (Petrovic et al., 2008) , therefore changes in P-gp could alter fetal accumulation of LPV. Furthermore, LPV is extensively metabolized by cytochrome P450 (CYP) 3A, a metabolizing enzyme that is sensitive to inflammationmediated changes in expression and functionality (Renton, 2001; Kumar et al., 2004) .
LPV is also highly bound (≥99%) to plasma proteins that can fluctuate during infection, mainly α1-acid glycoprotein (AAG) and, to a lesser extent, albumin, thus having the This article has not been copyedited and formatted. The final version may differ from this version. 
6 potential to affect the concentration of free drug available for intracellular and transplacental passage (Kumar et al., 2004; Chandwani and Shuter, 2008) .
Under the MTCT-prevention premise, the benefits of ARV therapy far outweigh the risks of fetal exposure to ARV drugs. However, the fetal safety of most ARV drugs has not been fully established and long-term effects of increased exposure are still unknown 
qRT-PCR and mRNA expression
Methods for RNA isolation, cDNA synthesis and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) have been previously described (Wang et al., 2005; Petrovic and Piquette-Miller, 2010) . Briefly, RNA was extracted from tissues (50-100 mg) using TRIzol reagent (Invitrogen, Burlington, ON). RNA was quantified using the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE) and then reverse-transcribed to cDNA by use of the First Strand cDNA synthesis kit (Fermentas, Burlington, ON) according to the manufacturer's protocol. Placental and hepatic mRNA expression levels of relevant genes were measured by qRT-PCR using the Roche LightCycler™ with the LC FastStart DNA Master SYBR Green I ® kit (Roche, Laval, QC). Oligonucleotides for previously reported primer sequences were synthesized at The Hospital for Sick Children (DNA Synthesis Centre, Toronto, ON) (Petrovic and Piquette-Miller, 2010) . All mRNA levels were normalized to 18s rRNA and the ratios are presented as the percentage of control values.
Lopinavir LC-MS/MS Assay
Samples and standards were prepared as previously described (Anger and PiquetteMiller, 2011 ) using a liquid-liquid extraction adapted from Wang et al. (Wang et al., 2006 
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9 volume of drug-free plasma or tissue homogenate was used for constructing LPV standards by adding to tubes containing pre-dried LPV. For plasma and hepatic samples, the final LPV standard concentrations ranged from 62.5-2000 ng/ml, whereas for fetal, and placental samples, the standards measured 6.25-200 and 25-1000 ng/ml, respectively. Ritonavir (RTV) was used as the internal standard (final concentration, 200 ng/ml). For extraction, 50µl of 500mM NaCO3 was mixed with the samples followed by (Applied Biosystems/MDS Sciex) for analysis of LPV and RTV peak areas and LPV quantification. The lower limit of detection was < 3 ng/ml and the lower limit of quantification was < 10 ng/ml.
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Pharmacokinetic Analysis
At each time point, plasma and hepatic tissue were obtained from 4 dams, while 3 fetuses and placentas were collected from each dam for a pooled analysis (per dam) of fetal and placental concentrations. Concentration-time curves, C(t) were obtained by plotting the average of data points. Since this study design entailed one-point sampling data (one blood or tissue sample from each rat), a non-compartmental analysis program for sparse sampling (Phoenix WinNonlin 6.3, Certara, St. Louis, MO) was utilized to calculate key pharmacokinetic parameters derived from maternal plasma concentrations.
Additionally, the Bailer method for destructive measurement sampling (Bailer, 1988; Hartmann et al., 2005; Zhou et al., 2008) was used to estimate the mean and S.E. of the maternal plasma AUC and the fetal, placental and hepatic tissue AUCs, from 5-120 min.
The Bailer method was previously adapted by Zhou et. al. to the following mathematical form (Zhou et al., 2008) : 
where n i is the number of the concentration data points at time t i . The variance of mean AUC is defined as 
Statistical analysis
Data were analyzed using Prism 6 (GraphPad Software, San Diego, CA). All results are expressed as means ± standard error (SE). With the exception of the pharmacokinetic analysis described above, for comparison of the effects between poly(I:C) and control, a two-tailed independent-samples t-test was used. Significance was assigned at α = 0.05, and is indicated as follows: *: p<0.05, **: p<0.01, and ***: p<0.001.
RESULTS
Interferon response to poly(I:C)
Interferon-gamma levels were examined in maternal plasma samples from poly(I:C)-treated and vehicle control rats. Viruses or administration of double stranded RNA such as poly(I:C) are known to induce Type I interfons and trigger an acute phase response.
Indeed, our ELISA results demonstrated a significant induction of IFN-γ, 24 hours after administration of 5.0 mg/kg poly(I:C), as compared to control (Figure 1 ). Measurements of IFN-γ were below detection limit in many control samples (11 out of 20) and were thus considered to be <10 pg/ml.
Effect of poly(I:C) on maternal drug transporter and Cyp3a2 expression
The impact of poly(I:C) on the expression of transporters in placental and hepatic tissues was examined by qRT-PCR (n=7-10/group) in order to confirm previously observed poly(I:C)-mediated changes in the expression of transporters that are reportedly implicated in LPV transport, namely the two P-gp isoforms Abcb1a and Abcb1b, as well as Abcc2 (Mrp2) (Agarwal et al., 2007; Petrovic and Piquette-Miller, 2010) .
In line with our previous observations, administration of poly(I:C) imposed significant changes in the expression of these transporters in the liver (Figure 2 ). After administration of 5.0 mg/kg poly(I:C), Abcb1a was significantly reduced to 61 ± 9% of control values, while Abcb1b was drastically increased (p < 0.05). Expression of hepatic Abcc2 (Mrp2) was significantly reduced to 61 ± 6% of control levels (p < 0.05).
Additionally, expression levels of the metabolizing enzyme Cyp3a2 were examined as downregulation has been reported in numerous models of acute and chronic In placenta, we also observed significant changes in the mRNA expression of examined transporters (Figure 2) . Placental Abcb1a and Abcb1b were significantly downregulated in poly(I:C)-treated dams, to 70 ± 9% and 66 ± 8% of control mRNA levels, respectively (p < 0.05). Abcc2 mRNA levels were decreased in the poly(I:C)-treated group to 44 ± 22% of control value, but this did not reach significance.
Influence of poly(I:C) on maternal and fetal LPV exposure
Maternal plasma, hepatic, placental and fetal LPV concentrations were determined by a validated LC-MS/MS assay, as described under Materials and Methods. Overall, our data showed that the fetal and placental LPV tissue concentrations were much lower than the maternal total plasma LPV concentrations indicating limited fetal distribution.
Plasma levels in the pregnant rats were in line with the typical clinical therapeutic range of LPV in HIV-infected patients. A significant increase in maternal plasma concentrations of LPV was seen in rats administered poly(I:C), as compared to vehicle control, with the most pronounced differences seen at 25-60 minutes after LPV administration ( Figure 3) . Table 1 summarizes the pharmacokinetic parameters calculated for both groups of pregnant rats. We obtained a terminal half-life of approximately 1.5 h, which is in line with previous reports (Kumar et al., 2004) . Plasma AUC between 5 and 120 min was significantly higher in the poly(I:C) group, (126 ± 13 in controls vs. 283 ± 28 μg*min/ml in poly(I:C)), as calculated by Bailer's method ( Table 2 ). The AUC 5-120 for fetal, placental and hepatic tissue concentrations did not differ significantly between the two groups (Table 2) , reflecting similar absolute tissue concentrations (Supplemental Figure 1) . However, when normalized to unbound LPV plasma concentrations, higher levels of accumulation were seen in these tissues at all time points, with significantly higher levels at 1-2 hrs (p < 0.05) (Figure 4 ).
DISCUSSION
Lopinavir is commonly used in HIV-infected pregnant women as part of highly active antiretroviral therapy, however the impact of co-existing conditions such as infection or inflammation on disposition is largely unknown (Watts, 2006; Lambert et al., 2011) .
Maintaining adequate drug concentrations is necessary as subtherapeutic concentrations can increase the risk of MTCT, while supratherapeutic concentrations can increase risk of drug toxicities (Ofotokun et al., 2011) .
In the present study, we examined the impact of an acute inflammatory response elicited by poly(I:C) on the disposition of LPV in pregnant rats. Consistent with induction of inflammation following a viral infection, we saw a dramatic increase in plasma concentrations of IFN-γ in the poly (I:C) group (Fortier et al., 2004; Petrovic and Piquette-Miller, 2010) . Likewise, the maternal plasma AUC 5-120min of LPV was significantly increased by more than 2-fold in the poly(I:C) group, suggesting that inflammation imposes changes in the pharmacokinetics of LPV. It is well recognized that induction of inflammation by bacteria or virus can cause changes in drug disposition (Morgan et al., 2008) .
Increased LPV levels in pregnant poly(I:C)-treated rats could occur through a number of mechanisms such as altered plasma protein binding, metabolism and distribution. LPV is highly bound (≥99%) to plasma proteins (Kumar et al., 2004; Chandwani and Shuter, 2008 ). An unbound fraction of 0.89% has been reported for LPV in serum from healthy pregnant women (Gulati et al., 2009) , which is comparable to the 0.85% we saw in the This article has not been copyedited and formatted. The final version may differ from this version. (Aweeka et al., 2010) . It is well known that inflammation can cause an induction of AAG (Schreiber et al., 1989) . In humans, the serum concentration of AAG rises two to five times during an acute phase response (Hochepied et al., 2003) . Various models of acute inflammation in rats have also demonstrated an increase in AAG levels resulting in altered pharmacokinetics of highly bound drugs (Murai-Kushiya et al., 1993; Laethem et al., 1994) . Consistent with reported increases in AAG, we found a significant increase in plasma protein binding of LPV in poly(I:C)-treated rats, as compared to control group. It is well established that inflammation can lead to changes in drug disposition through downregulation of drug metabolizing enzymes (Morgan, 1997; Renton, 2001 ). For example, impaired theophylline clearance during confirmed viral infection episodes is attributed to an IFN-mediated downregulation of CYP1A2-mediated metabolism. In humans, LPV is primarily cleared via CYP3A-mediated metabolism (Kumar et al., 2004; Chandwani and Shuter, 2008 (Waterschoot et al., 2010) . We measured the hepatic mRNA expression levels of Cyp3a2, the rat equivalent of CYP3A4 in humans, and we observed a significant downregulation in poly(I:C)-treated rats. This poly (I:C)-mediated downregulation is consistent with previous reports (Knickle et al., 1992; Petrovic and Piquette-Miller, 2010) . As plasma levels of metabolites were not measured in this study, the resultant effect of poly(I:C) on the hepatic clearance of LPV is not immediately obvious; however, previous studies have demonstrated that LPV metabolite concentrations in rats are reflective of Cyp3a2 mRNA levels (Anger and Piquette-Miller, 2011) . LPV is a highly extracted drug and is administered clinically with low-dose RTV in order to inhibit CYP3A enzymes and increase oral bioavailability. In this study we administered LPV intravenously in order to minimize variability due to intestinal transit times and circumvent the potential effects of poly(I:C) on intestinal and hepatic first pass extraction. Hepatic metabolism of highly extracted drugs such as LPV is more sensitive to changes in hepatic flow than to changes in plasma protein binding and intrinsic metabolism. Nevertheless it is still plausible that the decreased expression of Cyp3a along with increased plasma protein binding of LPV, could result in decreased hepatic metabolism, thereby contributing to altered LPV levels in the poly(I:C)-treated dams.
The co-ordinated activity of CYP3A with drug transporters can also impact systemic drug exposure (Benet and Cummins, 2001; Morgan et al., 2008) . LPV is transported by the apical drug efflux transporter P-gp. Several in vitro transport studies have demonstrated evidence that LPV is a substrate of P-gp, a finding that is also supported by This article has not been copyedited and formatted. The final version may differ from this version. 
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19 studies in an Abcb1 knockout mouse model (Agarwal et al., 2007; Janneh et al., 2007; Waterschoot et al., 2010) . We saw a decrease in mRNA expression of Abcb1a in the liver and placenta of poly(I:C)-treated rats. Interestingly, levels of Abcb1b were increased in maternal liver but decreased in placenta. We have previously shown that Pgp protein expression is decreased in the livers of poly(I:C) treated rats despite increased mRNA levels of Abcb1b (Petrovic and Piquette-Miller, 2010) . A decreased P-gp expression in liver could therefore contribute to a decreased hepatobiliary clearance of LPV. Indeed we saw increased hepatic levels of LPV (relative to unbound concentration)
in the pregnant rats that were administered poly(I:C), compared to controls. This could be due to decreased P-gp-mediated secretion of LPV into bile. Previous studies demonstrated that poly(I:C)-mediated changes in the expression of endogenous bile acid transporters were associated with elevated levels of bile acids in serum (Petrovic and Piquette-Miller, 2010) . It is likely that similar mechanisms are involved in the biliary transport of exogenous substrates, such as LPV. There is still speculation whether CYP3A is a greater determinant of LPV plasma concentrations in comparison with P-gp (Wyen et al., 2008; Waterschoot et al., 2010) , however our findings suggest that it is the combined action of these pathways that impact the overall LPV exposure, with evidence of the impact of P-gp on LPV tissue distribution. While we also observed a significant vivo disposition of LPV (Waterschoot et al., 2010) . Hence the role of this transporter on LPV disposition in pregnancy remains to be delineated.
It has been shown that placental transfer of LPV is highly variable, as evidenced by intersubject differences in the ratio of cord-to-maternal blood ranging from 5-25% (Gingelmaier et al., 2006) . Likewise cord-to-maternal ratios ranging from 7-43% are reported for nelfinavir (van Heeswijk et al., 2004) . As both P-gp expression and high plasma protein binding play important roles in restricting placental transfer of these agents, it is plausible that disease or inflammation-mediated changes could contribute to clinical variability. The observed decrease in placental expression of P-gp in the poly(I:C)-treated rats could lead to increased accumulation of drug substrates in fetal tissues. On the other hand, the observed inflammation-mediated increase in LPV plasma protein binding might lead to decreased transplacental transfer, as only free drug is able to cross cell membranes. Overall, we observed significant increases in LPV accumulation in placenta and fetal tissues of poly(I:C)-treated rats, when normalized to unbound plasma concentrations. This is in line with other studies that have shown an increase in accumulation of P-gp substrates attributed to decreased P-gp expression and activity. For instance, a markedly higher accumulation of the P-gp substrate 99m
Tcsestamibi was seen in fetal tissues isolated from endotoxin-treated dams (Wang et al., 2005) . Decreased P-gp expression and increased protein binding are opposing factors that attenuate the impact of inflammatory response on absolute tissue accumulation. To this point, when we examined the total (free and bound) concentrations of LPV in fetal tissues, the levels in poly(I:C) and control groups were not significantly different, group. This suggests that, in addition to altered plasma protein binding, decreased expression of the efflux transporters plays a role in LPV disposition. While LPV is clinically administered orally as a co-formulation with low-dose RTV in order to increase bioavailability, it has been reported that LPV binding to AAG is not affected by RTV at therapeutically relevant concentrations (Gulati et al., 2009 ).
In conclusion, our study in a rat model of viral infection demonstrated that inflammation-mediated changes in plasma protein binding, drug metabolism and drug transport significantly alter maternal and fetal disposition of LPV. It remains to be elucidated whether a similar trend would be seen in clinical cases of co-infection in pregnant women. As LPV metabolism and P-gp mediated transport appear highly comparable between rodents and humans (Kumar et al., 1999) , further clinical investigation of inflammation-mediated effects on LPV is warranted. Moreover as LPV is generally administered in combination with other antiretrovirals that are substrates of Pgp, MRP2, BCRP, and CYP3A (Kis et al., 2010) , the effects of inflammation on combination ARV therapies remain to be elucidated.
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